Oxford University's COVID-19 vaccine trial has only 50% chance of success
Falling rate of infection means success rate may drop to 50%
The Oxford University team in charge of developing a coronavirus vaccine said a decline in the infection rate will make it increasingly difficult to prove whether it's been successful, the Telegraph reported.
"It's a race against the virus disappearing, and against time," Professor Adrian Hill, director of the university's Jenner Institute, told the newspaper. "We said earlier in the year that there was an 80% chance of developing an effective vaccine by September. But at the moment, there's a 50% chance that we get no result at all."
Hill said he expects fewer than 50 of the 10,000 people who have volunteered to test the vaccine trial in coming week to catch the virus. If fewer than 20 test positive, the results may be useless, the newspaper cited him as saying.
Read more
- Your COVID-19 vaccine: $13.20 per shot planned by Indian biotech firm
- AstraZeneca to make Oxford vaccine as COVID-19 race heats up
- Coronavirus: Oxford University vaccine ready by September?
- Coronavirus: Indian woman part of Oxford University vaccine project receives social media 'encouragement'
- Oxford University vaccine in human trials from Thursday: UK Health Secretary
Although developers globally are working on as many as 100 experimental vaccines for COVID-19, the process is likely to take time. Finding a vaccine and distributing it globally will be a "massive moonshot," Dr. Michael Ryan, executive of director of the World Health Organization's Emergency Program, said earlier this month. There's a chance the disease may be here to stay, he said.
The British government has agreed to pay for as many as 100 million doses, adding that 30 million may be ready by September. The daily rate of new infections has fallen by almost two thirds since hitting a peak of almost 9,000 on April 10.
Separately, Reuters reported that Oxford University may join Moderna in a large-scale testing program in July.